EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cas9 degradation in human cells using phage anti-CRISPR proteins

Zuriah Meacham, Luisa Arake de Tacca, Joseph Bondy-Denomy, David Rabuka, Michael Schelle iD

PLOS Biology · 2023

DOI: 10.1371/journal.pbio.3002431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, 2023. Verfasst von Zuriah Meacham und 4 weiteren Autor:innen. Beteiligte Einrichtung: Acrigen Biosciences, Inc., Alameda, California, United States of America. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Bacteriophages. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacteriophages encode anti-CRISPR (Acr) proteins that inactivate CRISPR-Cas bacterial immune systems, allowing successful invasion, replication, and prophage integration. Acr proteins inhibit CRISPR-Cas systems using a wide variety of mechanisms. AcrIIA1 is encoded by numerous phages and plasmids, binds specifically to the Cas9 HNH domain, and was the first Acr discovered to inhibit SpyCas9. Here, we report the observation of AcrIIA1-induced degradation of SpyCas9 and SauCas9 in human cell culture, the first example of Acr-induced degradation of CRISPR-Cas nucleases in human cells. AcrIIA1-induced degradation of SpyCas9 is abolished by mutations in AcrIIA1 that break a direct physical interaction between the 2 proteins. Targeted Cas9 protein degradation by AcrIIA1 could modulate Cas9 nuclease activity in human therapies. The small size and specificity of AcrIIA1 could be used in a CRISPR-Cas proteolysis-targeting chimera (PROTAC), providing a tool for developing safe and precise gene editing applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsBacteriophagesHumansCRISPR-Associated Protein 9Gene EditingLysogeny

Substanzen

CRISPR-Associated Protein 9

Autor:innen und Institutionen

  • Acrigen Biosciences, Inc., Alameda, California, United States of America.
  • Department of Microbiology & Immunology, University of California, San Francisco, San Francisco, California, United States of America.

ORCID-Profile: Michael Schelle

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Meacham, Z., de Tacca, L. A., Bondy-Denomy, J., Rabuka, D., & Schelle, M. (2023). Cas9 degradation in human cells using phage anti-CRISPR proteins. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002431

Vancouver

Meacham Z, de Tacca LA, Bondy-Denomy J, Rabuka D, Schelle M. Cas9 degradation in human cells using phage anti-CRISPR proteins. PLOS Biology. 2023. doi:10.1371/journal.pbio.3002431

BibTeX
@article{Meacham2023,
  author = {Meacham, Zuriah and de Tacca, Luisa Arake and Bondy-Denomy, Joseph and Rabuka, David and Schelle, Michael},
  title = {Cas9 degradation in human cells using phage anti-CRISPR proteins},
  journal = {PLOS Biology},
  year = {2023},
  doi = {10.1371/journal.pbio.3002431}
}
Kostenlos starten →